Abstract:Despite the investment of considerable resources into the optimization of respiratory therapies, the incidence of bronchopulmonary dysplasia (BPD) in survivors of very preterm birth remains high. 1 While the exact pathophysiology of BPD remains to be fully elucidated, our understanding of the disease evolution has evolved from a dichotomous endpoint to a disease continuum that results from the complex interaction of postnatal lung injury and inflammation. 1 It is likely that within the BPD spectrum, distinct groups of infants will respond differently to injury triggers, in turn resulting in discrete phenotypes of lung injury and responses to interventions. The delineation of these phenotypes using emerging biomarkers such as plasma-derived proteins, measures of pulmonary mechanics and lung imaging is a growing area of research. 2 Not accounting for such phenotypes is a possible explanation for the disappointing lack of benefit demonstrated in multiple large clinical trials of strategies to reduce BPD. Postnatal corticosteroids are among the most heavily studied and controversial therapies aimed at reducing BPD. They have been used since the 1980s to prevent or treat BPD due to their potent anti-inflammatory properties to downregulate pulmonary inflammation and airway oedema. However, postnatal corticosteroids may have serious gastrointestinal and neurodevelopmental adverse effects and variation in the type and dosing regime of postnatal corticosteroids used may affect their effectiveness and side effect profile. A recent Cochrane review 3 concluded that systemic dexamethasone use after the first week of life in preterm infants at high risk of BPD was the only effective treatment based on the current evidence, with the combination of intratracheal budesonide mixed with surfactant looking promising but requiring further research. Despite nearly 100 clinical studies on postnatal corticosteroid use over the last 40 years, the strength of evidence for corticosteroid use to prevent or treat BPD is low to moderate at best, with further definitive well-designed clinical studies needed. Such clinical studies are expensive with long follow-up periods, and prone to recruitment failure. The challenge, therefore, lies in the identification of the right group of high-risk infants that will benefit most from the right corticosteroid treatment regime and timing. An objective pathophysiological lung disease marker may address these clinical and research challenges.

Reinitiating lung development: a novel approach in the management of bronchopulmonary dysplasia

Present and Future of Bronchopulmonary Dysplasia

Bronchopulmonary Dysplasia: 50 Years after the Original Description

Promises and challenges of stem cell cargo therapy for bronchopulmonary dysplasia

BPD: Latest Strategies of Prevention and Treatment

Nintedanib as a strategy to prevent bronchopulmonary dysplasia: dosing and tim(-ing) is of the essence

Diagnosis and management of bronchopulmonary dysplasia

Aberrant signaling pathways of the lung mesenchyme and their contributions to the pathogenesis of bronchopulmonary dysplasia.

Molecular mechanisms of cell death in bronchopulmonary dysplasia

Can pathophysiological lung function markers guide the use of postnatal corticosteroids for bronchopulmonary dysplasia?

Phenotypes of Bronchopulmonary Dysplasia

Integrative Studies of Human Cord Blood Derived Mononuclear Cells and Umbilical Cord Derived Mesenchyme Stem Cells in Ameliorating Bronchopulmonary Dysplasia

The emerging roles of microbiome and short-chain fatty acids in the pathogenesis of bronchopulmonary dysplasia

Impaired Pulmonary Vascular Development in Bronchopulmonary Dysplasia

An Innovative Model of Bronchopulmonary Dysplasia in Premature Infants

Vascular Endothelial Growth Factor as Molecular Target for Bronchopulmonary Dysplasia Prevention in Very Low Birth Weight Infants

Bronchopulmonary dysplasia: A review of pathogenesis and pathophysiology

Epigenetic modifications in the development of bronchopulmonary dysplasia: a review

Stem cell-derived extracellular vesicles: a potential intervention for Bronchopulmonary Dysplasia

[Methods for establishing animal model of bronchopulmonary dysplasia and their evaluation].